Organogenesis (ORGO)
(Delayed Data from NSDQ)
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.91 USD
-0.04 (-1.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth B Momentum C VGM
Zacks News
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 58.33% and 0.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organogenesis (ORGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 0.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Organogenesis Holdings has been struggling lately, but the selling pressure may be coming to an end soon.
Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet
by Zacks Equity Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.